Tramadol 150 mg capsule is available in the form of a white capsule is inscribed with gold ink on the cap “G232” and “150”.
As an opioid, the tramadol hydrochloride expansion-release capsule exposes users to the risks of addiction, misuse, and misuse. Because expanded release products such as tramadol hydrochloride expand-release capsules deliver opioid over an extended period of time, due to a large amount of tramadol, there is a greater risk of overdue and death.
- Tramadol 150 mg hydrochloride Extended-release capsules are also contraindicated in patients:
- Important respiratory depression
- Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitation equipment
- Known or suspected gastrointestinal disorders including paralysis ileus
- Hypersensitivity to tramadol (e.g., anaphylaxis)
Concurrent use of monoamine oxidase inhibitor (MAOI) or use within the last 14 days.
- Chronic pulmonary disease or life-threatening respiratory depression in patients in elderly, cactic, or debilitating patients
- Tramadol hydrochloride in patients with acute or severe bronchial asthma in an uncontrolled setting is contraindicated in the use of extended-release capsules or in the absence of resuscitation equipment.
2. Carefully monitor such patients, especially when the tramadol hydrochloride extends and titles the expanded-release capsules and when the tramadol hydrochloride extended-release capsule is given to other medicines which suppress respiration.
3. Patients of Chronic Pulmonary Disease: Tramadol Hydrochloride Extend-Release Capsule increases the risk of chronic obstructive pulmonary disease or respiratory deficiency in people with a significantly lower respiratory reserve, hypoxia, hyperthermia, or pre-existing respiratory depression.
4. Elderly, cachetic or debilitating patients: life-threatening respiratory depressants are more likely to occur in elderly, cachectic, or weaker patients because they may have pharmacokinetics or change clearance compared to young, healthy patients.
1. Addiction, Abuse, and Abuse
2. Life-breathing respiratory depression
3. Ultra-rapid metabolism of tramadol and other risk factors for life-threatening respiratory depression in children
4. Newborn Opioid Withdrawal Syndrome
5. Interaction with Benzodiazepines and other CNS Depressants
6. Serotonin syndrome
8. Adrenal insufficiency
9. Severe hypotension
10. Gastrointestinal adverse reaction
11. Hypersensitivity reaction
Tramadol hydrochloride expansion-release capsule with acute hypertrophy respiratory depression, progress for numbness or coma, skeletal muscle stiffness, cold and sticky skin, astringent students and, in some cases, pulmonary edema, bradycardia, Qt long, hypotension Can be revealed by, Partial or complete airway obstruction, atypical snoring, and death. Instead of mice, marked micrysis can be seen with hypoxia in overdose conditions.